Epidermal growth factor: Started Phase I/II trials

Seragen Inc. (SRGN), Hopkinton, Mass. Product: Epidermal growth factor (EGF) fusion toxin DAB389EGF Indication: Solid tumors expressing the EGF receptor in patients with persistent or recurrent malign...